• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » neuroinflammation

Articles Tagged with ''neuroinflammation''

AI generated illustration of a brain on fire
Neurology/psychiatric

Bioage nominates NLRP3 inhibitor as development candidate

Jan. 29, 2025
Bioage Labs Inc. has nominated BGE-102 as a development candidate. The orally available, small-molecule NLRP3 inhibitor has high potency and high brain penetration.
Read More
IPO, coins, financial chart

Septerna joins IPO queue; 23 biopharma debuts reach $5.9B

Oct. 3, 2024
By Karen Carey
South San Francisco-based Septerna Inc. filed an S-1 with the U.S. SEC to conduct an IPO on Nasdaq about two years and eight months after launching operations with a $100 million series A led by Third Rock Ventures. The company is focused on G protein-coupled receptor oral small molecules derived from its Native Complex Platform, aimed at treating diseases within the endocrinology, immunology and inflammation, and metabolic diseases realms.
Read More
Brain waves
Neurology/psychiatric

ECTRIMS 2024: Time for neuroprotection

Sep. 19, 2024
By Coia Dulsat
The Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen this week is celebrating its 40th edition. In recognition of this landmark, the plenary session and opening lecture were attended by Queen Margrethe of Denmark. Afterward, the hot topic session on neuroprotective therapies set the stage for the subsequent discussions on the latest trends in the management and treatment of multiple sclerosis (MS).
Read More
Neurology/psychiatric

MK2 inhibitor protects murine microglial cells from neuroinflammation

July 19, 2024
Cigarette smoke, the main cause of chronic obstructive lung disease, is considered a significant contributor of neuroinflammation, potentially leading to cognitive impairment and neurodegeneration. About 61% of individuals with chronic obstructive pulmonary disease have neurocognitive dysfunction.
Read More
Microglia and myelin
Neurology/psychiatric

BD2 inhibitor ABBV-744 demonstrates antineuroinflammatory effects in vivo

July 12, 2024
Researchers from the Chinese Academy of Sciences evaluated the highly potent and selective inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal (BET) family of proteins, ABBV-744, with the aim of assessing its preclinical efficacy and exploring the pathways by which the compound regulates microglia-mediated neuroinflammation.
Read More
Brain
Neurology/Psychiatric

Brain-penetrant TYK2 inhibitor shows efficacy in models of neuroinflammation

March 5, 2024
Researchers from Alumis Inc. have presented preclinical data for a novel, potential first-in-class tyrosine kinase 2 (TYK2) inhibitor – A-005.
Read More
Brain and blood cells
Neurology/Psychiatric

JR-14a attenuates neuroinflammation and reduces brain infarction following stroke

Feb. 12, 2024
Researchers from the University of Queensland and affiliated organizations recently presented preclinical data for the novel C3a receptor (C3aR) antagonist JR-14a, being developed as a neuroprotective agent for the treatment of post-stroke neuroinflammation.
Read More
Neurology/Psychiatric

Brain penetration profile of Nodthera’s NLRP3 inflammasome inhibitor described

Nov. 30, 2023
Aberrant NLRP3 inflammasome activation is at the root of a wide number of conditions, from heart, gastrointestinal, kidney or liver disorders to neuroinflammatory diseases such as Parkinson’s disease or multiple sclerosis. Researchers from Nodthera Ltd. have reported on NT-0796, an NLRP3 inflammasome inhibitor with an in vivo brain penetration profile.
Read More
Biomarkers

miR-92a confers protection against inflammation-driven neurodegeneration

Nov. 30, 2023
MicroRNAs (miRNAs) play an important role in modulating neuronal stress responses, but their impact on neuroprotection has been poorly studied. Multiple sclerosis (MS) is the most common inflammatory disease affecting the central nervous system. Researchers have recently attempted to identify potential miRNAs that play a protective role in neuroinflammation.
Read More

Merck cuts big AI deals with Benevolentai and Exscientia

Sep. 20, 2023
By Lee Landenberger
Merck KGaA has entered deals that could bring U.K. artificial intelligence companies Benevolentai Ltd. and Exscientia plc more than $1.2 billion. Oxford, U.K.-based Exscientia and Merck will collaborate to find three small-molecule candidates in oncology, neuroinflammation and immunology. Exscientia is getting $20 million up front and could bring in $674 million in milestones payments.
Read More
Previous 1 2 3 4 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 10, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe